{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"378","upperLimit":"946","value":"547"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"}],"units":"Participants"}],"description":"All patients were administered the following drugs;\n\n1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3\n2. Melphalan 140mg/m2 IV on day -2\n3. Stem cell infusion on day 0\n4. Campath 20mg IV on day -7,-6,-5,-4, and -3","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients were administered the following drugs;\n\n1. Fludarabine 30mg/m2 intravenously daily at the same time over 30 min on days -7,-6,-5,-4, and -3\n2. Melphalan 140mg/m2 IV on day -2\n3. Stem cell infusion on day 0\n4. Campath 20mg IV on day -7,-6,-5,-4, and -3","id":"OG000","title":"T-cell Depleted Allogeneic Stem Cell Transplantation"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Patients evaluated continuously with disease specific re-evaluation at day 30, 3 months, 6 months, 1 year, and as indicated thereafter up to 10 years","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"Days"}